clinical trial · NCT06174649
Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial
Gram-negative BacteremiaBloodstream InfectionReveal
brief summary
This study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized 1:1 to have the positive blood cultures characterized using standard of care (SOC) antimicrobial susceptibility testing (AST) vs. a rapid AST method known as Reveal™ in addition to SOC AST. The purpose of the FAST trial is to evaluate whether use of a rapid phenotypic AST improves clinical outcomes compared to use of SOC AST methods in clinical settings with high resistance rates.
started
Dec 22, 2023
primary completion
Jun 18, 2025
completion
Jun 18, 2025
last updated
Jul 28, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol